175 related articles for article (PubMed ID: 30870217)
1. Arthritis risk with immune checkpoint inhibitor therapy for cancer.
Pundole X; Abdel-Wahab N; Suarez-Almazor ME
Curr Opin Rheumatol; 2019 May; 31(3):293-299. PubMed ID: 30870217
[TBL] [Abstract][Full Text] [Related]
2. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
Subedi A; Williams SG; Yao L; Maharjan S; Strauss J; Sharon E; Thomas A; Apolo AB; Gourh P; Hasni SA; Gulley JL; Kaplan MJ; Katz JD; Gupta S
JAMA Netw Open; 2020 Feb; 3(2):e200032. PubMed ID: 32101306
[TBL] [Abstract][Full Text] [Related]
3. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
4. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.
Roberts J; Ennis D; Hudson M; Ye C; Saltman A; Himmel M; Rottapel R; Pope J; Hoa S; Tisseverasinghe A; Fifi-Mah A; Maltez N; Jamal S
Autoimmun Rev; 2020 Aug; 19(8):102595. PubMed ID: 32535092
[TBL] [Abstract][Full Text] [Related]
5. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
Jeurling S; Cappelli LC
Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.
Roberts J; Smylie M; Walker J; Basappa NS; Chu Q; Kolinsky M; Lyddell C; Ye C
Clin Rheumatol; 2019 May; 38(5):1513-1519. PubMed ID: 30701346
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
[TBL] [Abstract][Full Text] [Related]
8. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
9. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
Jamal S; Hudson M; Fifi-Mah A; Ye C
J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
[TBL] [Abstract][Full Text] [Related]
10. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review.
Crout TM; Lennep DS; Kishore S; Majithia V
Curr Rheumatol Rep; 2019 May; 21(6):28. PubMed ID: 31115712
[TBL] [Abstract][Full Text] [Related]
11. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.
Smith MH; Bass AR
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):362-366. PubMed ID: 29125905
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
Williams SG; Mollaeian A; Katz JD; Gupta S
Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
14. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
15. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N; Suarez-Almazor ME
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
[TBL] [Abstract][Full Text] [Related]
16. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
17. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.
Kim ST; Murphy WA; Aparicio A; Subudhi SK
J Immunother Precis Oncol; 2020 Aug; 3(3):128-132. PubMed ID: 35663254
[TBL] [Abstract][Full Text] [Related]
18. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
[TBL] [Abstract][Full Text] [Related]
19. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis?
Sibilia J; Friess S; Schaeverbeke T; Maloisel F; Bertin P; Goichot B; Kuntz JL
J Rheumatol; 1999 Jan; 26(1):115-20. PubMed ID: 9918251
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]